MIRM: financial statements from SEC — TradeAlmanac

MIRM

Mirum Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	160m	133m	128m	112m	90m	78m
Cost of revenue	29m	26m	23m	23m	21m	20m
Selling, general and administrative	96m	62m	63m	58m	51m	49m
Operating expenses	949m	130m	133m	127m	103m	102m
Operating income	−789m	3m	−5m	−15m	−13m	−24m
Pre-tax income	−790m	3m	−5m	−14m	−14m	−24m
Income tax	475,000	−262,000	402,000	1m	347,000	635,000
Net income	−790m	3m	−6m	−15m	−14m	−25m
Earnings per share	−13.43	0.06	−0.12	−0.30	−0.30	−0.52
Earnings per share, diluted	−13.43	0.05	−0.12	−0.30	−0.30	−0.52
Weighted average shares	59m	51m	50m	49m	48m	47m
Weighted average shares, diluted	59m	57m	50m	49m	48m	47m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	325m	297m	282m	228m	212m	223m	223m	233m
Short-term investments	61m	87m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−229m	−2m
Depreciation and amortisation	7m	6m
Share-based compensation	36m	16m
Capital expenditure	664,000	41,000
Investing cash flow	−12m	−16m
Financing cash flow	270m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)